Developing personalised therapies for Uveal Melanoma: Understanding disease process and validation of therapeutic targets

By: Frances Drummond | Posted on: 08 Nov 2019

Developing personalised therapies for Uveal Melanoma: Understanding disease process and validation of therapeutic targets
Prof Breandán N Kennedy

 

Start year: 2019

End year: 

Principal Investigator: Prof Breandán N Kennedy

Institution: UCD Conway Institute, University College Dublin

Grant funding: BCR project grant

Linked Breakthrough Research Priorities: 1, 2, 3, 4, 5

Prof Breandán N Kennedy, is a professor of Biomolecular & Biomed Science in the Conway Institute.  The goal of his research team is to develop genetic and pharmacological treatments for human blindness.

Uveal melanoma (UV) is a cancer of the eye involving the iris, ciliary body, or choroid (collectively referred to as the uvea).  Ireland has a very high incidence of this cancer, with some experts speculating that it is one of the highest incidences worldwide.  

 

The Uveal Melanoma research programme in UCD is a collaborative network of national and international collaborators.  The aim of this funding is to further understand personalised disease mechanisms and treatment in UM.  

Dr Kayleigh Slater, a postdoctoral scientist with this network, discusses the need for this research: 

"There are currently no targeted therapies available for the treatment of metastatic uveal melanoma and standard chemotherapies afford patients a poor median survival of between 4-15 months. Research into new therapeutic targets for this often devastating disease is therefore critical to improve patient outcomes. This research is particularly important here in Ireland as the incidence of uveal melanoma here is now believed to be one of highest in the world." 

 

 

  

  

 

© Site Designed by Granite Digital